SCHEMBL5543219

SCHEMBL5543219

[O]c1ccc(N2CCN(Cc3ccccc3OC(F)(F)F)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.47
CNR1 P21554 1/20 0.46
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 2/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 2/20 0.45
LMNA P02545 2/20 0.44
EPHX2 P34913 4/20 0.44
HTR7 P34969 2/20 0.44
TRPC5 Q9UL62 1/20 0.44
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
SCN9A Q15858 1/20 0.43
MEN1 O00255 1/20 0.43
MGLL Q99685 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CHRM4 P08173 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544651 0.90 KMT2A (0.45) KMT2AKDM4EALDH1A1GAAMAPT
SCHEMBL5543227 0.87 DRD4 (0.55) KMT2ACNR1KDM4EALDH1A1GAA
SCHEMBL5543488 0.80 KDM4E (0.61) KMT2AKDM4EALDH1A1GAAMAPT
SCHEMBL5543082 0.78 KMT2A (0.74) KMT2AKDM4EALDH1A1GAAMAPT
SCHEMBL27891441 0.78 CYP2A13 (0.58) KMT2AALDH1A1EPHX2ALOX15MEN1
SCHEMBL5543380 0.78 KMT2A (0.48) KMT2AKDM4EALDH1A1GAAMAPT
SCHEMBL24093239 0.78 DRD2 (0.60) KMT2AKDM4EALDH1A1EPHX2MEN1
SCHEMBL5544655 0.78 DRD4 (0.52) KMT2AKDM4EALDH1A1GAAMAPT
SCHEMBL5543182 0.76 ALDH1A1 (0.62) ALDH1A1MAPTTSHRCHRM4
SCHEMBL28000125 0.76 MGLL (0.57) KMT2AKDM4EALDH1A1HTTEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KMT2A 4267/4885CNR1 857/4885KDM4E 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.